Keytruda (Pembrolizumab)
pembrolizumab 100 mg/4 mL injection, 4 mL vial · INJECTION · PBS code 15299F
STREAMLINEDWhat it costs
AU$3632.56 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-04-01.
- • Repeats: 7.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
High risk locally advanced carcinoma of the cervix
Initial treatment
Patient must have high-risk, locally advanced cervical cancer of one of the following types: (i) squamous cell carcinoma, (ii) adenosquamous carcinoma, (iii) adenocarcinoma; AND
The treatment must be/have been commenced in combination with concurrent chemoradiotherapy; AND
Patient must have a WHO performance status of 1 or less; AND
Patient must not have received prior PBS-subsidised treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for carcinoma of the cervix; AND
The treatment must not exceed a total of (i) 24 months, (ii) 35 doses (based on a 3-weekly dose regimen), (iii) 17 doses (based on a 6-weekly dose regimen) whichever comes first from the first dose of this drug regardless if it was PBS/non-PBS subsidised; AND
Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 7 repeat prescriptions; or
Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
High risk locally advanced carcinoma of the cervix
Continuing treatment
Patient must have previously received PBS-subsidised treatment with this drug for this indication; AND
Patient must not have experienced disease recurrence while being treated with this drug for this indication; AND
The treatment must be the sole PBS-subsidised anti-cancer therapy for this condition; AND
The treatment must not exceed a total of (i) 24 months, (ii) 35 doses (based on a 3-weekly dose regimen), (iii) 17 doses (based on a 6-weekly dose regimen) whichever comes first from the first dose of this drug regardless if it was PBS/non-PBS subsidised; AND
Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 7 repeat prescriptions; or
Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.
Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd ABN 14 000 173 508
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.